

Eva Segelov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4507321/publications.pdf>

Version: 2024-02-01

132
papers

2,884
citations

186209

28
h-index

197736

49
g-index

134
all docs

134
docs citations

134
times ranked

4805
citing authors

#	ARTICLE	IF	CITATIONS
1	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2017, 18, 1159-1171.	5.1	293
2	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. <i>Pancreas</i> , 2017, 46, 707-714.	0.5	241
3	PTEN mutations are common in sporadic microsatellite stable colorectal cancer. <i>Oncogene</i> , 2004, 23, 617-628.	2.6	135
4	Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1543-1557.	5.1	129
5	International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAACT. <i>Journal of Clinical Oncology</i> , 2020, 38, 2510-2518.	0.8	92
6	Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus. <i>Cancer Treatment Reviews</i> , 2016, 47, 32-45.	3.4	74
7	Effect of Fractional Carbon Dioxide Laser vs Sham Treatment on Symptom Severity in Women With Postmenopausal Vaginal Symptoms. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1381.	3.8	70
8	Management of advanced gastric cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 199-209.	1.4	69
9	Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. <i>JAMA Oncology</i> , 2018, 4, 1597.	3.4	68
10	The Aetiological Role of Human Papillomavirus in Oesophageal Squamous Cell Carcinoma: A Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e69238.	1.1	67
11	Cisplatin-based chemotherapy for ovarian germ cell malignancies: the Australian experience.. <i>Journal of Clinical Oncology</i> , 1994, 12, 378-384.	0.8	66
12	Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. <i>The Cochrane Library</i> , 2017, 6, CD007047.	1.5	60
13	Physical activity and fitness in women with metastatic breast cancer. <i>Journal of Cancer Survivorship</i> , 2014, 8, 647-656.	1.5	58
14	Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1577-1598.	0.5	58
15	Practical Considerations for Treating Patients With Cancer in the COVID-19 Pandemic. <i>JCO Oncology Practice</i> , 2020, 16, 467-482.	1.4	56
16	Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. <i>Clinical Colorectal Cancer</i> , 2018, 17, e617-e629.	1.0	54
17	Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2258-2264.	0.8	52
18	Recurrence in Resected Gastroenteropancreatic Neuroendocrine Tumors. <i>JAMA Oncology</i> , 2018, 4, 583.	3.4	49

#	ARTICLE	IF	CITATIONS
19	Randomized Evaluation of Cognitive-Behavioral Therapy and Graded Exercise Therapy for Post-Cancer Fatigue. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 74-84.	0.6	45
20	Targeted therapy for metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 991-1006.	1.1	44
21	Redressing the balance - The ethics of not entering an eligible patient on a randomised clinical trial. <i>Annals of Oncology</i> , 1992, 3, 103-105.	0.6	35
22	Physical Activity for Symptom Management in Women With Metastatic Breast Cancer: A Randomized Feasibility Trial on Physical Activity and Breast Metastases. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 929-939.	0.6	35
23	Loss of special AT-rich sequence-binding protein 1 (SATB1) predicts poor survival in patients with colorectal cancer. <i>Histopathology</i> , 2014, 65, 155-163.	1.6	33
24	Everolimus in the management of metastatic neuroendocrine tumours. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 132-141.	1.4	33
25	Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review. <i>Endocrine</i> , 2017, 57, 366-375.	1.1	33
26	Circulating epigenetic biomarkers for detection of recurrent colorectal cancer. <i>Cancer</i> , 2020, 126, 1460-1469.	2.0	33
27	Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) \leq 2 cm: Study Protocol for a Prospective Observational Study. <i>Frontiers in Medicine</i> , 2020, 7, 598438.	1.2	33
28	Alterations of the Birt-Hogg-Dube gene (BHD) in sporadic colorectal tumours. <i>Journal of Medical Genetics</i> , 2003, 40, 511-515.	1.5	31
29	Current opinion on optimal treatment for colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 597-611.	1.1	30
30	Pilot study evaluating the role of cardiac magnetic resonance imaging in monitoring adjuvant trastuzumab therapy for breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012, 8, 95-100.	0.7	28
31	The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. <i>British Journal of Cancer</i> , 2014, 111, 1122-1131.	2.9	28
32	Long term response to chemotherapy in patients with visceral metastatic melanoma. <i>Annals of Oncology</i> , 1994, 5, 249-251.	0.6	27
33	Role of human papillomaviruses in esophageal squamous cell carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013, 9, 12-28.	0.7	27
34	Influence of Population Immunosuppression and Past Vaccination on Smallpox Reemergence. <i>Emerging Infectious Diseases</i> , 2018, 24, 646-653.	2.0	25
35	The Role of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 2567-2579.	0.9	25
36	COVID-19 vaccination rates, intent, and hesitancy in patients with solid organ and blood cancers: A multicenter study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 570-577.	0.7	24

#	ARTICLE	IF	CITATIONS
37	The Impact of Histological Review on Clinical Management of Testicular Cancer. <i>British Journal of Urology</i> , 1993, 71, 736-738.	0.1	23
38	Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. <i>PLoS ONE</i> , 2015, 10, e0135599.	1.1	22
39	Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2018, 47, 321-325.	0.5	22
40	Supportive oncofertility care, psychological health and reproductive concerns: a qualitative study. <i>Supportive Care in Cancer</i> , 2020, 28, 809-817.	1.0	22
41	Improving the impact of didactic resident training with online spaced education. <i>ANZ Journal of Surgery</i> , 2013, 83, 477-480.	0.3	20
42	JRK is a positive regulator of β -catenin transcriptional activity commonly overexpressed in colon, breast and ovarian cancer. <i>Oncogene</i> , 2016, 35, 2834-2841.	2.6	20
43	SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. <i>British Journal of Cancer</i> , 2018, 119, 1332-1338.	2.9	19
44	An update on the use of immunotherapy in patients with colorectal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 291-304.	1.4	18
45	Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Recent Advances and Ongoing Challenges. <i>Clinical Colorectal Cancer</i> , 2021, 20, 29-41.	1.0	18
46	Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer. <i>BMC Cancer</i> , 2005, 5, 89.	1.1	15
47	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. <i>BMC Cancer</i> , 2016, 16, 339.	1.1	15
48	Integrative molecular analysis of colorectal cancer and gastric cancer: What have we learnt?. <i>Cancer Treatment Reviews</i> , 2019, 73, 31-40.	3.4	15
49	Cancer and Indigenous Populations: Time to End the Disparity. <i>JCO Global Oncology</i> , 2020, 6, 80-82.	0.8	15
50	Serious Underlying Medical Conditions and COVID-19 Vaccine Hesitancy: A Large Cross-Sectional Analysis from Australia. <i>Vaccines</i> , 2022, 10, 851.	2.1	15
51	AMTRA: a multicentered experience of a web-based monitoring and tailored toxicity management system for cancer patients. <i>Supportive Care in Cancer</i> , 2021, 29, 859-867.	1.0	14
52	Oncofertility as a Universal Right and a Global Oncology Priority. <i>JCO Global Oncology</i> , 2020, 6, 314-316.	0.8	13
53	Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1477-1493.	1.1	12
54	The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]. <i>PLoS ONE</i> , 2020, 15, e0229900.	1.1	12

#	ARTICLE	IF	CITATIONS
55	Risk factors, epidemiology, screening, and prognostic factors in female genital cancer. <i>Current Opinion in Oncology</i> , 1992, 4, 913-922.	1.1	11
56	Identifying and prioritising gaps in colorectal cancer trials research in Australia. <i>Medical Journal of Australia</i> , 2012, 197, 507-511.	0.8	11
57	Uncommon Anal Neoplasms. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 143-161.	0.6	11
58	The Economic Impact on Australian Patients with Neuroendocrine Tumours. <i>Patient</i> , 2020, 13, 363-373.	1.1	11
59	Follow-Up for Resected Gastroenteropancreatic Neuroendocrine Tumours: A Practice Survey of the Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) and the North American Neuroendocrine Tumor Society (NANETS). <i>Neuroendocrinology</i> , 2018, 107, 32-41.	1.2	10
60	Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 63-70.	1.6	10
61	Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, 313-319.	1.0	9
62	Towards new models of cancer care in Australia: lessons from Victoria's response to the COVID-19 pandemic. <i>Internal Medicine Journal</i> , 2020, 50, 1282-1285.	0.5	9
63	Medical Oncologists' Perspectives on How the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer. <i>Oncologist</i> , 2020, 25, 229-234.	1.9	9
64	Impact of the COVID-19 Epidemic on a Pan-Asian Academic Oncology Clinical Trial. <i>JCO Global Oncology</i> , 2020, 6, 585-588.	0.8	9
65	Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects. <i>Cancer Management and Research</i> , 2020, Volume 12, 5819-5830.	0.9	8
66	Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours. <i>Oncotarget</i> , 2020, 11, 2636-2646.	0.8	8
67	Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. <i>Clinical Colorectal Cancer</i> , 2010, 9, 8-14.	1.0	7
68	Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 557-571.	1.1	7
69	Cancer care disparities among Australian and Aotearoa New Zealand Indigenous peoples. <i>Current Opinion in Supportive and Palliative Care</i> , 2021, 15, 162-168.	0.5	7
70	A Machine-Learning-Based Bibliometric Analysis of the Scientific Literature on Anal Cancer. <i>Cancers</i> , 2022, 14, 1697.	1.7	7
71	A Case-Control Study of the Role of Human Papillomavirus in Oesophageal Squamous Cell Carcinoma in Australia. <i>Journal of Oncology</i> , 2014, 2014, 1-7.	0.6	6
72	Identifying and Prioritizing Gaps in Neuroendocrine Tumor Research: A Modified Delphi Process With Patients and Health Care Providers to Set the Research Action Plan for the Newly Formed Commonwealth Neuroendocrine Tumor Collaboration. <i>Journal of Global Oncology</i> , 2017, 3, 380-388.	0.5	6

#	ARTICLE	IF	CITATIONS
73	Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis. Expert Review of Anticancer Therapy, 2018, 18, 339-349.	1.1	6
74	Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: A cohort study of two cancer centres. International Journal of Surgery, 2018, 51, 71-75.	1.1	6
75	A 2020 update of anal cancer: the increasing problem in women and expanding treatment landscape. Expert Review of Gastroenterology and Hepatology, 2020, 14, 665-680.	1.4	6
76	Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research: Perspectives of Research Needs in Anal Cancer. Clinical Colorectal Cancer, 2021, 20, 279-287.	1.0	6
77	InterAACT: An international multicenter open label randomized phase II advanced anal cancer trial comparing cisplatin (CDDP) plus 5-fluorouracil (5-FU) versus carboplatin (CBDCA) plus weekly paclitaxel (PTX) in patients with inoperable locally recurrent (ILR) or metastatic disease.. Journal of Clinical Oncology, 2015, 33, TPS792-TPS792.	0.8	6
78	Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours. Cancer Medicine, 2021, 10, 8405-8411.	1.3	6
79	Barriers and enablers to cancer clinical trial participation and initiatives to improve opportunities for rural cancer patients: A scoping review. Clinical Trials, 2022, 19, 464-476.	0.7	6
80	Anti-cancer therapy made easier: a 25-year update. Internal Medicine Journal, 2021, 51, 473-480.	0.5	5
81	Phase II trial PD-L1/PD-1 blockade avelumab with chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer: The Ave-Rec trial.. Journal of Clinical Oncology, 2019, 37, TPS3622-TPS3622.	0.8	5
82	The Disease Influenced Vaccine Acceptance Scale-Six (DIVAS-6): Validation of a Measure to Assess Disease-Related COVID-19 Vaccine Attitudes and Concerns. Behavioral Medicine, 0, , 1-10.	1.0	5
83	Acute leukaemia following chemotherapy including etoposide for testicular carcinoma. Australian and New Zealand Journal of Medicine, 1993, 23, 718-719.	0.5	4
84	Mechanisms determining sensitivity to cisplatin in three mutant Chinese hamster ovary cell lines. Mutation Research DNA Repair, 1998, 407, 243-252.	3.8	4
85	Reasons to try RIME™. Medical Education, 2007, 41, 1104-1104.	1.1	4
86	Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care. Journal of Clinical Medicine, 2019, 8, 1455.	1.0	4
87	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. Expert Review of Anticancer Therapy, 2020, 20, 251-270.	1.1	4
88	The EUS molecular evaluation of pancreatic cancer: A prospective multicenter cohort trial. Endoscopic Ultrasound, 2021, 10, 335-343.	0.6	4
89	Medical Oncology Group of Australia position statement: COVID-19 vaccination in patients with solid tumours. Internal Medicine Journal, 2021, 51, 955-959.	0.5	4
90	Dihydropyrimidine dehydrogenase deficiency in patients with severe toxicity after 5-fluorouracil: a retrospective single-center study. Annals of Gastroenterology, 2020, 34, 68-72.	0.4	4

#	ARTICLE	IF	CITATIONS
91	Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET). <i>BMC Infectious Diseases</i> , 2022, 22, 70.	1.3	4
92	Excellent Response to MEK Inhibition in an <i>AGK-BRAF</i> Gene Fusion Driven Carcinoma: Case Report and Literature Review. <i>Anticancer Research</i> , 2022, 42, 373-379.	0.5	4
93	Atherosclerotic Cardiovascular Risk With Combination Avelumab and Axitinib. <i>Journal of Clinical Oncology</i> , 2022, 40, 3467-3469.	0.8	4
94	Chemotherapy made easier. <i>Australian and New Zealand Journal of Medicine</i> , 1993, 23, 387-392.	0.5	3
95	Tetranucleotide and Low Microsatellite Instability Are Inversely Associated with the CpG Island Methylator Phenotype in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 3529.	1.7	3
96	MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). <i>BMC Cancer</i> , 2021, 21, 932.	1.1	3
97	Patients' preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile?. <i>Journal of Clinical Oncology</i> , 2018, 36, 3602-3602.	0.8	3
98	The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab.. <i>Journal of Clinical Oncology</i> , 2018, 36, 719-719.	0.8	3
99	Performance comparison of the methylated <i>BCAT1</i> / <i>IKZF1</i> ctDNA test (COLVERA) with the CEA assay for detection of recurrent colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3589-3589.	0.8	3
100	Cost-Effectiveness of Aspirin Adjuvant Therapy in Early Stage Colorectal Cancer in Older Patients. <i>PLoS ONE</i> , 2014, 9, e107866.	1.1	3
101	The emperor's new clothes - can chemotherapy survive?. <i>Australian Prescriber</i> , 2006, 29, 2-3.	0.5	3
102	High-Risk Human Papillomavirus in Esophageal Squamous Cell Carcinoma"Letter. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 408-408.	1.1	2
103	Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 951-964.	1.1	2
104	The commonwealth neuroendocrine tumour collaboration (CommNETs) and North American neuroendocrine tumor society (NANETS) endorsement and update of European neuroendocrine tumor society (ENETS) best practice consensus for lung neuroendocrine tumors (LNET). <i>Annals of Oncology</i> , 2018, 29, viii473.	0.6	2
105	Developing clinical indicators for oncology: the inaugural cancer care indicator set for the Australian Council on Healthcare Standards. <i>Medical Journal of Australia</i> , 2021, 214, 528-531.	0.8	2
106	Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis. <i>Clinical Colorectal Cancer</i> , 2021, 20, 236-244.	1.0	2
107	Impact of chemotherapy partner on efficacy of targeted therapy in metastatic colorectal cancer (mCRC): A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3552-3552.	0.8	2
108	COVID-19 vaccinations for patients with cancer: many remain unvaccinated despite having priority in the vaccine rollout. <i>Internal Medicine Journal</i> , 2021, 51, 1760-1760.	0.5	2

#	ARTICLE	IF	CITATIONS
109	Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer. JNCI Cancer Spectrum, 2021, 5, pkaa107.	1.4	2
110	Global Oncology Authorship and Readership Patterns. JCO Global Oncology, 2022, 8, e2100299.	0.8	2
111	The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours. Targeted Oncology, 2022, 17, 95.	1.7	2
112	The role of human papillomaviruses in oesophageal squamous cell carcinoma: a review of the evidence. International Journal of Infectious Diseases, 2012, 16, e351-e352.	1.5	1
113	Physical Activity For Women With Metastatic Breast Cancer. Medicine and Science in Sports and Exercise, 2015, 47, 464.	0.2	1
114	Is there a place for Ramucirumab after Sorafenib in patients with advanced HCC?. Hepatobiliary Surgery and Nutrition, 2019, 8, 546-548.	0.7	1
115	Multifocal hepatic steatosis mimicking malignancy in two siblings. JGH Open, 2019, 3, 346-348.	0.7	1
116	1875P Voluntary assisted dying in Victoria, Australia: A case series. Annals of Oncology, 2020, 31, S1068.	0.6	1
117	Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer. Translational Andrology and Urology, 2021, 10, 1688-1699.	0.6	1
118	Meta-analysis of outcomes of VEGF and EGFR targeted biologic therapy in relapsed metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 534-534.	0.8	1
119	Results of the Quad wild type arm of the AGITG ICECREAM study: A randomised phase II study of cetuximab alone or in combination with irinotecan in patients with refractory metastatic colorectal cancer with no mutations in KRAS, NRAS, BRAF or PIK3CA.. Journal of Clinical Oncology, 2017, 35, 3572-3572.	0.8	1
120	The Relationship between Human Papillomavirus and Oesophageal Squamous Cell Carcinoma in China—A Review of the Evidence. Advances in Infectious Diseases, 2013, 03, 17-34.	0.0	1
121	Global Multidisciplinary Team Meetings: Challenging Cases Virtual Forums from the International Multidisciplinary Anal Cancer Conference (IMACC). Clinical Colorectal Cancer, 2022, , .	1.0	1
122	Follow-up and recurrence in resected gastroenteropancreatic neuroendocrine tumours: A population-based study. Annals of Oncology, 2017, 28, v153.	0.6	0
123	Adjuvant anti-VEGF therapy for overall survival and relapse-free survival in patients with resected non-metastatic colorectal cancer. The Cochrane Library, 0, , .	1.5	0
124	Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 2020, 20, 305-324.	1.1	0
125	Physical activity and fitness in women with metastatic breast cancer.. Journal of Clinical Oncology, 2013, 31, 136-136.	0.8	0
126	Prospective evaluation of KRAS, NRAS, BRAF, and PI3KCA mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan Cetuximab Evaluation and the Cetuximab Response) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 of Clinical Oncology, 2014, 32, e14536-e14536.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Is there a role for epidermal growth factor receptor inhibition in the treatment of advanced esophagogastric tumours?. <i>Translational Cancer Research</i> , 2016, 5, S1214-S1221.	0.4	0
128	Development of follow up recommendations for completely resected gastroenteropancreatic neuroendocrine tumours (GEP-NETS): Practice Survey of Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) in conjunction with North American Neuroendocrine Tumour Society (NANETS).. <i>Journal of Clinical Oncology</i> , 2017, 35, 224-224.	0.8	0
129	Escalated dose somatostatin analogues (SSAs) in management of neuroendocrine tumors (NETs): A systematic review.. <i>Journal of Clinical Oncology</i> , 2017, 35, 422-422.	0.8	0
130	COX2 and HLA immunohistochemical (IHC) staining in colorectal tumour samples from patients participating in the ASCOLT clinical trial of adjuvant aspirin therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 695-695.	0.8	0
131	Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 188-188.	0.8	0
132	Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 39-51.	1.1	0